The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2007Everyday Action Impairment in People with Parkinson's Disease Dementia/Dementia with Lewy Bodies
Objective/Rationale:
Parkinson’s disease (PD) and Parkinson’s Disease Dementia/Dementia with Lewy Bodies (PDD/DLB) have been associated with cognitive deficits and everyday action impairment (EAI; e.g... -
Rapid Response Innovation Awards, 2007Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions
Objective/Rationale:
When experimental treatments involve neurosurgery, researchers often use a placebo condition called sham surgery, which involves an invasive procedure (e.g., partial thickness... -
Rapid Response Innovation Awards, 2007Re-distribution of Brain Gangliosides for Treatment of Parkinson's Disease
Project Description:
A pre-clinical model of Parkinson's disease can be generated by injecting MPTP, a toxin that results in specific damage to the same part of the brain that is damaged in Parkinson's...
-
Rapid Response Innovation Awards, 2007Neuroprotective effects of isradipine in a pre-clinical model of Parkinson’s disease
Objective/Rationale:
Recent work by our group has shown that blocking L-type Ca2+ channels protects vulnerable dopaminergic neurons in three animal models Parkinson’s disease (PD). Isradipine, a high... -
Rapid Response Innovation Awards, 2007Genetic characterization of Omi/Htra2 (PARK13) in autosomal dominant and sporadic Parkinson’s disease
Objective/Rationale:
Identification of DNA variations that cause familial/sporadic parkinsonism has provided insight into the biological pathways involved in disease. Thirteen loci (PARK1-13) have... -
The Role of Inflammation in Parkinson's Disease, 2004The role of TNF-mediated dopaminergic neurotoxicity in Parkinson's disease: Novel anti-TNF biologics as biochemical tools and new therapeutic agents
In July 2004, at the one-year assessment of our initial grant under the Foundation's Inflammation initiative, we demonstrated that our novel dominant-negative TNFs offered significant in vivo...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.